A new study indicates that the loss of brain volume associated with the Alzheimer's drug lecanemab shows the drug is working ...

(12/16) complete response rate observed in relapsed/refractory AL Amyloidosis patients with median 4 prior lines of ...

The members of the Amyloid imaging to prevent Alzheimer's disease (AMYPAD) have announced the publication of a perspective ...

A loss of brain volume associated with new immunotherapies for Alzheimer's disease may be caused by the removal of amyloid ...

This important study identifies the "H-state" as a potential conformational marker distinguishing amyloidogenic from non-amyloidogenic light chains, addressing a critical problem in protein misfolding ...

Behold the Body. Electron microgram of a Biondi body shows a dense core surrounded by filaments that bind gold-labeled secondary antibody to TMEM239 (black dots). [Courtesy of Ghetti et al., 2024.] ...

Italian researchers have developed a nasal spray showing promise in slowing Alzheimer's progression. Tests on mice with ...

The earlier MCI due to AD and mild AD dementia are diagnosed and treated, the greater the opportunity for benefit.

Alzheimer’s disease is a long, slow neurodegenerative calamity, and scientists are still hunting for blood biomarkers that reflect all its specific stages. At the Clinical Trials on Alzheimer’s ...

In mice, inhibiting protein S-palmitoylation Counteracted accumulation of harmful proteins in neurons and delayed onset and progression of cognitive decline.

Prothena is also evaluating birtamimab, a wholly-owned potential treatment for AL amyloidosis. PRTA reached a Special Protocol Assessment agreement with the FDA and initiated a confirmatory phase III ...